Unlearn.AI: collaboration with Merck KGaA
Unlearn.AI has announced a multi-year collaboration agreement with Merck KGaA, focused on using tech to accelerate late-stage trials. Planned solutions include the use of Digital Twins, which are comprehensive, longitudinal predictions of a patient’s prognosis on a control treatment.
“We are very pleased to establish this collaboration with Merck KGaA, Darmstadt, Germany, and to be working with its world-class team who shares our vision for how AI and other innovative technologies can expand access to new medicines,” said Charles Fisher, founder and CEO of Unlearn. “Our solution has successfully proven that it can reduce the size of control arms by 30% or more and generate reliable clinical evidence in a fraction of the time.”
